German scientists have released research that states the drug reboxetine (Edronax) which has been routinely prescribed for depression over the last thirteen years is no more effective than a placebo. The BMJ study furthermore states that it is possibly harmful and that the manufacturer has been guilty of suppressing trials results. It is implied that NICE will have to review their guidance on the prescribing of the drug.Read the full article:
Read the original abstract
No comments:
Post a Comment